Article List

WPRIM Management System> DCMS> Cancer Research and Treatment> 2014> 46> 4

Volume: 46 Issue: 4

1. Reply to Commentary on "A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians".	Page:426—426
2. Commentary on "A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians".	Page:425—425
3. Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy.	Page:419—424
4. Pleural Metastasis as Initial Presentation of Occult Gastric Cardia Cancer: A Possible Role of PET-CT in Diagnosis.	Page:415—418
5. A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib.	Page:411—414
6. Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors.	Page:403—410
7. Ultra-Low-Dose Chest CT in Patients with Neutropenic Fever and Hematologic Malignancy: Image Quality and Its Diagnostic Performance.	Page:393—402
8. p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors.	Page:383—392
9. Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?.	Page:374—382
10. Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors.	Page:366—373
11. Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents.	Page:358—365
12. Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma.	Page:348—357
13. Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor.	Page:339—347
14. Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.	Page:331—338
15. Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.	Page:323—330